Mingpun Warunee, Saiyarat Wilarat, Nimworapan Mantiwee, Penthinapong Thitichaya, Dilokthornsakul Piyameth
Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Pharmacy Division, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand.
Clin Transl Sci. 2025 Mar;18(3):e70192. doi: 10.1111/cts.70192.
A target heart rate of 55-60 beats per minute is a goal for propranolol in both primary and secondary prophylaxis of variceal hemorrhage (VH). However, dose adjustments are often needed based on baseline heart rates. This study analyzed the effect of heart rate reduction from baseline with propranolol therapy on VH in patients with cirrhosis. A retrospective study was conducted on cirrhotic patients receiving propranolol for primary and secondary prophylaxis, 2008-2023. Patients were categorized as responders or non-responders based on the achievement of a heart rate reduction of ≥ 25% from baseline. The primary outcome was the incidence of VH. A survival analysis with propensity score-inverse probability treatment weighting was performed to associate heart rate reduction and the outcome. Among the 215 patients treated with propranolol for primary prophylaxis, 72 (33.5%) were responders and 143 (66.5%) non-responders. In secondary prophylaxis, 157 patients were included, with 52 (33.1%) classified as responders and 105 (66.9%) as non-responders. The median Child-Pugh score was 6 (range 5-12) for primary and 7 (range 5-12) for secondary prophylaxis. Responders and non-responders showed a similar incidence of VH in both primary (adjusted hazard ratio (HR) 1.70, 95% CI: 0.82-3.49) and secondary prophylaxis (adjusted HR 1.00, 95% CI: 0.34-2.90). Our analysis did not support achieving a heart rate reduction of ≥ 25% from baseline as a response to propranolol for the primary and secondary prophylaxis of VH in cirrhosis.
在静脉曲张出血(VH)的一级和二级预防中,普萘洛尔的目标心率是每分钟55 - 60次。然而,通常需要根据基线心率进行剂量调整。本研究分析了普萘洛尔治疗使心率从基线降低对肝硬化患者VH的影响。对2008年至2023年接受普萘洛尔进行一级和二级预防的肝硬化患者进行了一项回顾性研究。根据心率从基线降低≥25%将患者分为反应者或无反应者。主要结局是VH的发生率。采用倾向评分逆概率治疗加权的生存分析来关联心率降低与结局。在215例接受普萘洛尔一级预防的患者中,72例(33.5%)为反应者,143例(66.5%)为无反应者。在二级预防中,纳入了157例患者,其中52例(33.1%)被归类为反应者,105例(66.9%)为无反应者。一级预防的Child-Pugh评分中位数为6(范围5 - 12),二级预防为7(范围5 - 12)。在一级预防(调整后风险比(HR)1.70,95%置信区间:0.82 - 3.49)和二级预防(调整后HR 1.00,95%置信区间:0.34 - 2.90)中,反应者和无反应者的VH发生率相似。我们的分析不支持将心率从基线降低≥25%作为肝硬化患者VH一级和二级预防中对普萘洛尔反应的指标。